SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 6

Emerging biomarker for predicting acute kidney injury after cardiac surgery: cystatin C

Onur SAYDAM
Ercan TÜRKMEN
Oytun PORTAKAL
Mustafa ARICI
Rıza DOĞAN
Metin DEMİRCİN
İlhan PAŞAOĞLU
Mustafa YILMAZ
Pages
1096–1103
Publication Date
2018-12-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to our study, serum CysC was a reliable biomarker that may aid in the early detection and follow-up of AKI after cardiac surgery.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Cardiopulmonary bypass (CPB)-associated acute kidney injury (AKI) is a common situation and rapid diagnosis and risk classification are important in the prevention and management of AKI.
📊
Key Findings & Data:Changes in serum creatinine (SCr) levels in the current consensus criteria do not allow clinicians to diagnose CPB-associated AKI until 48 h after surgery.
💡
Conclusion & Impact:According to our study, serum CysC was a reliable biomarker that may aid in the early detection and follow-up of AKI after cardiac surgery.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Acute kidney injury · biomarker · cardiac surgical procedures

Abstract

Background/aim: Cardiopulmonary bypass (CPB)-associated acute kidney injury (AKI) is a common situation and rapid diagnosis and risk classification are important in the prevention and management of AKI. Changes in serum creatinine (SCr) levels in the current consensus criteria do not allow clinicians to diagnose CPB-associated AKI until 48 h after surgery. Materials and methods: We conducted a prospective single center study involving 57 patients who underwent cardiac surgery with CBP to compare serum beta-trace protein (BTP), neutrophil gelatinase-associated lipocalin-2 (NGAL), and cystatin C (CysC) levels with SCr for early diagnosis of CPB associated AKI. We defined AKI according to KDIGO criteria. Results: AKI was diagnosed in 24 (42.1%) patients. Mean duration of postoperative intensive care unit stay was 4.79 (± 6.12) days for the AKI+ group and 2.15 (± 0.56) days for the AKI- group. The average length of hospital stay was 8.13 (± 5.75) days for the AKI+ group and 7.21 (± 3.68) days for the AKI- group, which was significantly longer in the AKI+ group (P < 0.001, P = 0.011). Unlike other biomarkers, a significant increase in postoperative CysC levels was always found in patients with AKI during follow-up when compared to patients in whom AKI did not develop (P < 0.001). Conclusion: Increase in serum CysC levels showed a significant positive correlation with increase in SCr levels. We have not seen this correlation between other biomarkers and SCr. According to our study, serum CysC was a reliable biomarker that may aid in the early detection and follow-up of AKI after cardiac surgery.

🔖

Cite This Article

SAYDAM, O., TÜRKMEN, E., PORTAKAL, O., ARICI, M., DOĞAN, R., DEMİRCİN, M., PAŞAOĞLU, İ., YILMAZ, M. (2018). Emerging biomarker for predicting acute kidney injury after cardiac surgery: cystatin C. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 6, 1096–1103. https://ajindex.com/articles/113832

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006; 1: 19-32.
  2. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, War - nock DG, Levin A, Acute Kidney Injury Network. Acute Kid- ney Injury Network: report of an initiative to improve out- comes in acute kidney injury. Crit Care. 2007; 11: R31. Acute Kidney Injury Work Group. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter, Suppl 2012; 2: 1-138.
  3. Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: physiological principles. Intensive Care Med 2004; 30: 33-37.
  4. Cholongitas E, Shusang V, Marelli L, Nair D, Thomas M, Patch D, Burns A, Sweny P, Burroughs AK. Review article: renal function assessment in cirrhosis - difficulties and alternative measurements. Aliment Pharmacol Ther 2007; 26: 969-978.
  5. Gaygisiz U, Aydogdu M, Badoglu M, Boyaci N, Gullu Z, Gursel G. Can admission serum cystatin C level be an early marker subclinical acute kidney injury in critical care patients? Scand J Clin Lab Invest 2016: 1-8.
  6. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is su- perior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
  7. Priem F, Althaus H, Birnbaum M, Sinha P, Conradt HS, Jung K. Beta-trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range. Clin Chem 1999; 45: 567-568.
  8. Bökenkamp A, Franke I, Schlieber M, Düker G, Schmitt J, Buderus S, Lentze MJ, Stoffel-Wagner B. Beta-trace protein— a marker of kidney function in children: “Original research communication-clinical investigation”. Clin Biochem 2007; 40: 969-975.
  9. Spanaus KS, Kollerits B, Ritz E, Hersberger M, Kronenberg F, von Eckardstein A, Mild, Moderate Kidney Disease Study Group. Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary non- diabetic chronic kidney disease. Clin Chem 2010; 56: 740-749.
  10. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Bar - asch J, Devarajan P. Identification of neutrophil gelatinase-as- sociated lipocalin as a novel early urinary biomarker for isch- emic renal injury. J Am Soc Nephrol 2003; 14: 2534-2543.
  11. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neu- trophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004; 24: 307-315.
  12. Wagener G, Gu